Elämänlaatu ja vatsaoireet pitkään hoidetuilla ihokeliakiapotilailla : poikkileikkaustutkimus Suomessa by Pasternack, Camilla
    
 
 
 
i 
 
 
 
 
ELÄMÄNLAATU JA VATSAOIREET PITKÄÄN HOIDETUILLA 
IHOKELIAKIAPOTILAILLA: POIKKILEIKKAUSTUTKIMUS SUOMESSA. 
 
 
 
 
Camilla Pasternack 
 Syventävien opintojen kirjallinen työ 
Tampereen yliopisto 
Lääketieteen yksikkö 
Keliakiatutkimusryhmä 
Marraskuu 2015  
    
 
 
 
ii 
___________________________________________________________________________ 
Tampereen yliopisto 
Lääketieteen yksikkö 
 
PASTERNACK CAMILLA, KAUKINEN KATRI, KURPPA KALLE, MÄKI MARKKU, COLLIN PEKKA, 
REUNALA TIMO, HUHTALA HEINI, SALMI TEEA. QUALITY OF LIFE AND GASTROINTESTINAL 
SYMPTOMS IN LONG-TERM TREATED DERMATITIS HERPETIFORMIS PATIENTS: A CROSS-SECTIONAL 
STUDY IN FINLAND. AM J CLIN DERMATOL 2015. DOI: 10.1007/S40257-015-0149-1 
Kirjallinen työ, 15 sivua 
Ohjaajat: Sisätautiopin professori Katri Kaukinen ja ihotautien EL, tohtori Teea Salmi 
 
Marraskuu 2015 
 
Avainsanat: ihokeliakia, elämänlaatu, vatsavaivat, gluteeniton ruokavalio 
___________________________________________________________________________ 
Ihokeliakia on klassisen keliakian ihoilmentymä, jota hoidetaan keliakian tavoin elämän mittaisella, 
tiukalla, gluteenittomalla ruokavaliolla. Hoidetuilla keliakiapotilailla on enemmän vatsavaivoja ja 
heidän elämänlaatunsa on huonompi kuin terveellä väestöllä. Vatsavaivojen esiintymistä tai 
elämänlaatua ei kuitenkaan ole tutkittu ihokeliakiapotilailla. Tutkimuksessa selvitetään, kärsivätkö 
myös pitkään gluteenittomalla ruokavaliolla hoidetut ihokeliakiapotilaat jatkuvista vatsaoireista ja 
onko heidän elämänlaatunsa alentunut.  
Tässä poikkileikkaustutkimuksessa tutkittiin 78 ihokeliakiapotilasta. Heidän vatsavaivojaan 
arvioitiin Gastrointestinal Symptom Rating Scale -kyselyn avulla. Elämänlaatua ja hyvinvointia 
tutkittiin käyttämällä Psychological General Well-Being- ja Short Form 36-kyselyitä. Tuloksia 
verrattiin 110 terveen verrokin muodostamaan kohorttiin, väestön referenssiarvoihin sekä 371 
hoidettuun keliakiakontrolliin.  
Ihokeliakia potilaiden mediaani-ikä oli 57 vuotta ja 51 % heistä oli miehiä. Merkitseviä eroja ei 
löydetty vatsavaivojen tai elämänlaadun suhteen, kun ihokeliakiapotilaita verrattiin kontrolleihin, 
mutta ihokeliakiapotilaat kärsivät vähemmän vatsavaivoista kuin keliakiakontrollit, ja heidän 
elämänlaatunsa oli parempi. Naispuolisilla ihokeliakiapotilailla oli kuitenkin vaikeampia 
vatsavaivoja, ja he olivat vähemmän tarmokkaita kuin miesihokeliakiapotilaat. Iho-oireen 
esiintyvyys, gluteenittoman ruokavalion kesto tai siinä pysyvyys ei vaikuttanut elämänlaatuun tai 
vatsavaivojen vaikeuteen.  
Pitkään gluteenittomalla ruokavaliolla hoidetut ihokeliakia potilaat eivät siis kärsi gluteenittoman 
ruokavalion aiheuttamasta tautitaakasta, ja heidän elämänlaatunsa on terveiden verrokkien tasolla. 
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Abstract 
 
Background: Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac disease. Both 
conditions are treated with a restrictive life-long gluten-free diet (GFD). Treated coeliac disease 
patients have been shown to have more gastrointestinal symptoms and inferior quality of life 
compared to healthy controls, but evidence regarding quality of life in DH is lacking. Objective: 
The aim was to evaluate whether long-term GFD-treated DH patients suffer from persistent 
gastrointestinal symptoms and if they experience a drawdown in quality of life. Methods: 
Gastrointestinal symptoms and quality of life were assessed in 78 long-term GFD-treated DH 
patients using validated “Gastrointestinal Symptom Rating Scale”, “Psychological General Well-
Being” and “Short Form 36” questionnaires. The findings were compared to 110 healthy controls, 
population-based reference values and 371 treated coeliac disease-controls. Results: The median 
age of the DH patients at the time of the study was 57 years, and 51% were male. Significant 
differences in gastrointestinal symptoms or quality of life were not detected when treated DH 
patients were compared to healthy controls, but treated DH patients had less gastrointestinal 
symptoms and increased quality of life compared to coeliac disease-controls. Female DH patients 
had more gastrointestinal symptoms and reduced vitality compared to male DH patients. The 
presence of skin symptoms nor the adherence or duration of GFD did not have any influence on 
gastrointestinal symptoms or quality of life.  
Conclusion: We conclude that long-term GFD-treated DH patients do not suffer from the burden of 
dietary treatment and have a quality of life comparable to that of controls. 
 
Key points: 
• Long-term gluten-free diet treated DH patients did not experience more gastrointestinal 
symptoms nor had a decline in the quality of life compared to healthy controls.  
• Gluten-free diet treated DH women had more gastrointestinal symptoms and decline in 
vitality compared to DH men
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1 Introduction 
 
Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac disease, occurring in 
approximately 12% of coeliac disease patients. [1] DH manifests as an itchy, blistering rash 
predominantly on the extensor surfaces of elbows and knees, and on the buttocks and scalp. [2]  The 
diagnosis of DH is based on typical clinical manifestation and the demonstration of granular 
immunoglobulin (Ig) A deposits in the papillary dermis. [3] The majority of DH patients evince 
small-bowel mucosal villous atrophy characteristic of coeliac disease, and the remainder have 
coeliac-type inflammation in the gut. Regardless of the mucosal damage, DH patients are thought to 
suffer only rarely from gastrointestinal symptoms or have signs of malabsorption. [4, 5]  
The treatment of choice for coeliac disease and DH is a strict life-long gluten-free diet (GFD). 
The diet has a positive effect on the small-bowel mucosal villous atrophy and it also alleviates 
gastrointestinal complaints and malabsorption and the DH rash. [6, 7] A long-lasting strict GFD has 
also been shown to reduce the risk of malignant diseases such as lymphoma associated with DH and 
coeliac disease. [8] However, the diet is hard to comply with and it causes drawdown in life quality 
because of its life-long restrictive nature, which interferes with everyday life. [9-11] Furthermore, 
the diet is more expensive than the normal gluten-containing diet.  
Coeliac disease patients have been found to have a quality of life inferior to that in general 
population at the time of diagnosis. [12, 13] Even though health-related quality of life (HRQoL) has 
been shown to improve concomitant with treatment, [12, 14] in most studies the HRQoL of long-
term GFD-treated coeliac disease patients does not reach the level of the normal population. [14-17] 
Furthermore, coeliac disease patients have been shown to suffer from persistent gastrointestinal 
complaints even after a long-term GFD. [18, 19] DH is a chronic itching skin disease and patients 
adhere to the same burdensome GFD as coeliac disease patients, but little is known about HRQoL 
in DH. The aim of this study was to establish whether the burden of restrictive GFD causes a 
drawdown in DH patients’ HRQoL or do the benefits of decreased symptoms overcome the 
negative effects of GFD. Further, we aimed to find out whether treated DH patients suffer from 
persistent gastrointestinal symptoms. The results were compared to healthy controls and treated 
coeliac disease-controls. 
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2 Materials and Methods 
2.1 Patients and controls 
This was a cross-sectional study on the Finnish DH population. The cohort was derived from 
an adult coeliac disease series, including altogether 1111 patients. The series was recruited 
nationwide between the years 2006 and 2010 by advertising in national and local coeliac disease 
societies and using newspaper advertisement. Personal or telephone interviews were conducted to 
the recruited either by a physician or a study nurse specialized in coeliac disease. The interviews 
included questions about demographic data, the year of DH or coeliac disease diagnosis, skin 
symptoms, coeliac disease-associated disorders, family history of coeliac disease or DH, duration of 
the diet and strictness of GFD at the time of the study. The strictness of the diet was assessed based 
on the interviews and patients were distributed into four groups: 1. strict diet, no dietary lapses, 2. 
dietary lapses less than once a week, 3. dietary lapses more than once a week and 4. unrestricted 
gluten-containing diet (Table 1). In addition, validated questionnaires about gastrointestinal 
symptoms, HRQoL and psychological general well-being were mailed to those enrolled.  
Out of the 1111 recruited patients, 569 patients over 18 years answered to the validated 
questionnaires. Out of these 569, 78 patients had been diagnosed with DH and they were enrolled as 
cases in the study group. The medical records of the DH patients were reviewed to verify that all 
had had skin symptoms compatible with DH at the time of diagnosis, and that the presence of skin 
immunoglobulin A (IgA) deposits in the papillary dermis was confirmed by direct 
immunofluorescence. [3] 
DH patients’ gastrointestinal symptoms and quality of life as measured by the Psychological 
General Well-Being (PGWB) questionnaire were compared to 110 healthy controls, who considered 
themselves healthy and had no first-degree relatives with coeliac disease. These healthy controls 
were recruited from the immediate neighbourhood and among friends of the coeliac disease 
patients. The aim was to obtain a control group from a social and residential environment similar to 
that of the study patients. The median age of the healthy control group was 48 years (range 23-87) 
and 19% were male (Table 1). The results of the Short Form SF-36 (SF-36) questionnaire were 
compared to the age- and gender-adjusted Finnish general population reference values obtained 
from a nationwide health survey involving 2060 subjects: 45% were male and the mean age was 49  
years (standard deviation 17), median not known. [20] Furthermore, 371 GFD-treated coeliac 
disease patients suffering from abdominal symptoms at the time of the diagnosis, were selected as a 
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coeliac disease-controls from the same series where DH patients were chosen. The biopsy-proven 
coeliac disease diagnoses were verified from the medical records. In the coeliac disease control 
group, 19% of patients were male and the median age at the time of the study was 56 years (range 
19-92) (Table 1).  
All participants gave their written informed consent. The study protocol was approved by the 
Regional Ethics Committee of Tampere University Hospital.  
 
2.2 Methods 
Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale 
(GSRS), which is a 15-item questionnaire used to evaluate common gastrointestinal symptoms in 
five different groups: diarrhoea, indigestion, constipation, abdominal pain and reflux. The 
questionnaire uses a seven-grade Likert scale for each item, one symbolizing no symptoms and 
seven indicating the most severe symptoms. A higher score thus indicates more symptoms. The 
final scores are calculated as a mean for each sub-dimension and the total GSRS score as the mean 
of all 15 items. [21] 
The quality of life was assessed with PGWB and SF-36 questionnaires. The PGWB is a 
questionnaire  used to assess health-related quality of life and well-being. This is a 22-item 
questionnaire which includes six emotional states: anxiety, depressed mood, self-control, positive 
well-being, general health and vitality. All of the items use a six-grade Likert scale, where a value 
of one represents the poorest and value six the best possible well-being. The total score ranges 
therefore between 22 and 132 points, a higher score indicating better quality of life. [22] The SF-36 
is a generic HRQoL questionnaire, which uses eight parameters to quantify the quality of life. These 
are: general health perceptions, physical functioning, mental health, social functioning, vitality, 
bodily pain, physical role functioning and emotional role functioning. A scoring algorithm is used 
to transform the raw scores on each question into a scale ranging from 0-100, higher scores 
indicating better quality of life. [23] All of the questionnaires have been widely used in coeliac 
disease research and were chosen in view of their comparability with previous research and their 
good validity and reproducibility. [14, 24, 25] 
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2.3 Statistics 
The data were analysed with the IBM SPSS Statistics 20 software package (International 
Business Machines Corp., New York, USA) in cooperation with a statistician. Since the data were 
not normally distributed, median values and interquartile ranges were calculated for all GSRS and 
PGWB parameters. Statistical significances were tested by Mann-Whitney U-test. P values <0.05 
were considered statistically significant. The data with significance were further adjusted by gender 
and age. In order to make the values comparable with the reference, in SF-36 the means and 
standard deviations were used to describe the results. Significances between DH patients and the 
Finnish reference values were evaluated by estimating the confidence intervals for the differences in 
means. 
3 Results  
 
Forty (51%) of the 78 DH patients were male (Table 1). The median age of the DH patients at the 
time of the diagnosis was 38 years and at the time of the current study 57 years. At the time of the 
diagnosis all DH patients were shown to have IgA deposits detected by direct immunofluorescence 
in skin biopsies. Twenty-two out of the 41 (54%) DH patients with available small-bowel biopsy 
result at the time of the diagnosis had subtotal villous atrophy, 13 (32%) had partial villous atrophy, 
and 6 (14%) evinced normal villous architecture. At the time of the study, 95% of the DH patients 
were on a strict GFD, and the median duration of the diet was 18 years. None of the DH patients 
was consuming a normal gluten-containing diet (Table 1). At the time of the study  73 out of 78 
(94%) DH patients had negative endomysial antibodies.  
When the GFD-treated DH patients were compared to healthy controls, a non-significant trend 
emerged in GSRS reflux score, DH patients having more symptoms than healthy controls. 
However, this significance disappeared when adjusted for gender and age (Table 2). No other 
differences between DH patients and healthy controls were found in GSRS scores (Table 2). DH 
patients did not differ from healthy controls in the PGWB total or any sub-dimension scores. Only 
the unadjusted general health score was inferior in DH patients compared to healthy controls, but 
again the divergency disappeared when adjusted for gender and age (Table 2). Significant 
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differences were not detected between DH study patients and healthy controls when the different 
aspects of quality of life were measured by SF-36 questionnaire (Fig. 1). 
At the time of the diagnosis, 191 out of 309 (62%) coeliac disease patients with available data had 
subtotal villous atrophy in the small bowel mucosa, 109 (35%) had partial villous atrophy and 9 
(3%) minor coeliac enteropathy. At the time of the study endomysial antibodies were negative in 
350 out of 369 (95%) coeliac disease patients. When the GFD-treated DH patients were compared 
to treated coeliac disease-controls, DH patients had statistically significantly less symptoms in 
GSRS total and GSRS sub-dimension scores diarrhoea and pain. When data was adjusted for gender 
and age, only the difference in GSRS total score remained significant (Table 2). No differences 
were found in PGWB scores between treated DH patients and coeliac disease-controls. (Table 2) 
However, in SF-36 questionnaire coeliac disease-controls had significantly lower scores compared 
to DH patients in physical function, role physical and general health sub-dimension scores. There 
was also a non-significant trend in bodily pain. When the results were adjusted by gender and age, 
significance remained in general health and role physical sub-dimensions (Fig. 1). 
When DH women were compared to DH men, a statistically significant difference was found in the 
GSRS parameters ‘total’ and ‘constipation’, DH women having more symptoms than DH men. A 
similar trend for women to experience more symptoms than men was also seen in other parameters 
of the GSRS questionnaire (Table 3). In PGWB and SF-36, a significant difference between the 
genders was found in vitality, which was inferior in DH women in both questionnaires (Table 3). In 
SF-36, there was also a borderline significant difference (P= 0.061) in mental health, showing 
poorer mental health in DH women compared to DH men (Table 3). No gender differences were 
found in coeliac disease-control group (data not shown). 
Seventeen per cent of DH patients (13 out of 78) reported having visible skin symptoms compatible 
with DH or pruritus at the time of the study (Table 1), but the presence or absence of skin symptoms 
had no influence on GSRS, PGWB or SF-36 scores (data not shown). Similarly, neither adherence 
to nor duration of GFD had any effect on the presence of persistent skin symptoms or on the 
questionnaire scores when the results were compared within the DH cohort. 
4 Discussion 
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This is the first large study focusing on gastrointestinal symptoms and quality of life in a long-
term GFD-treated cohort of DH patients. We found that long-term GFD-treated DH patients do not 
suffer from the burden of a GFD nor from the burden of the disease itself, as their quality of life 
was found to be comparable to that of the general population. Since HRQoL is known to be reduced 
in other comparable chronic itching skin diseases such as psoriasis and atopic dermatitis [26-28] the 
fact that our DH patients well-being is comparable to controls could be due to the very specific and 
curative treatment of GFD. 
GFD-treated DH patients did not suffer from gastrointestinal complaints unlike coeliac disease 
patients who have been shown to suffer from persistent gastrointestinal complaints even when 
maintaining a strict GFD. [18, 19, 29] In Finland after long-term GFD 96% of coeliac disease 
patients have shown to evince normal villous architecture in small bowel biopsies. [30] In this study 
95% and 98% of DH and coeliac disease patients followed a strict GFD and 94% and 95% of DH 
and coeliac disease patients were seronegative supporting excellent clinical and histological 
recovery on GFD in both groups.  It has been suggested that the explanation for the persistent 
gastrointestinal symptoms in GFD-treated coeliac disease patients lies in the low amount of fibre in 
the diet [29, 31] or in trace amounts of gluten. [32] However, DH patients follow exactly the same 
strict GFD as coeliac disease patients. Diagnostic delay and severity of gastrointestinal symptoms 
prior to diagnosis are known to be factors increasing the risk of prolonged gastrointestinal 
symptoms in coeliac disease. [19] DH patients are thought to suffer from milder gastrointestinal 
symptoms before the diagnosis but research has been unable to show a difference in the duration of 
symptoms prior to diagnosis between DH and coeliac disease. [33] Also the composition and 
diversity of the duodenal microbiota have been shown to vary between untreated classical coeliac 
disease and DH. [34] Although it has not been studied how GFD-treatment changes the duodenal 
microbiota, the difference in duodenal microbiota might have a role in explaining the difference in 
gastrointestinal symptoms between treated DH and coeliac disease patients. Moreover, the 
prevalence of irritable bowel syndrome-type symptoms has been found to be significantly higher in 
patients with coeliac disease compared to the normal population, [15, 35] while there is no evidence 
of this in DH. Thus coexisting undiagnosed gastrointestinal disorders might also influence the 
incidence of gastrointestinal symptoms in coeliac disease patients.  
DH skin symptoms are known to alleviate comparatively slowly with GFD-treatment only, [4] 
and hence dapsone is a medication that is often used for a few months to a few years in combination 
with dietary treatment to reduce the skin symptoms more quickly. [4] We did not have data about 
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the use of dapsone in our study population and therefore in patients with ongoing skin symptoms 
dapsone usage cannot be excluded even though dapsone is not commonly used in DH patients with 
a long duration of GFD. Although not scientifically studied in DH, the presence of skin symptoms 
are known to affect poorly the patients’ quality of life. In our data only 13 DH patients were 
suffering from skin symptoms at the time of the study, and therefore it is possible that we were 
unable to show the effect of the skin symptoms to the quality of life due to the small cohort size. In 
addition, instead of using dermatological questionnaires, we used generic quality of life 
questionnaires, which might have limited accuracy to show the effect of skin symptoms on HRQoL. 
In our study cohort we found DH women to have more gastrointestinal complaints, especially 
constipation, compared to DH men. Coeliac disease women are also known to suffer from increased 
gastrointestinal symptoms compared to men, [18, 29] although our data showed no gender 
difference in coeliac-disease control group. In addition, more women than men are known to suffer 
from irritable bowel syndrome and especially constipation-predominant condition. [36] In this study 
DH women showed also lower vitality compared to DH men, which would imply that women with 
DH feel more tired and worn out compared to DH men. A similar distinction between the genders in 
HRQoL parameters has been widely observed previously in coeliac disease, [24, 25, 29] even 
though not evident in this current study. Interestingly this gender distinction in HRQoL is not found 
in all chronic diseases such as type-2 diabetes patients. [37] 
In contrast to previous coeliac disease research, we focused here solely on DH patients and our 
DH cohort size was large. Previous research on HRQoL in DH has been scant; to our knowledge, 
only Tontini et al. [38] have focused on this aspect. In their coeliac disease study, they assessed the 
HRQoL of a small subcohort of 10 DH patients with the Italian version of the SF-36 questionnaire. 
Similarly to ourselves, they found no differences in the HRQoL of treated DH patients when 
compared to a control group. In addition to cohort size, other strengths of our study were the 
nationwide approach and the well-verified skin biopsy-proven DH diagnosis. Control patients did 
not undergo gastroscopy and small bowel biopsy to exclude coeliac disease, but even if there were a 
few asymptomatic coeliac disease patients among controls this would not have influenced the 
results. In addition, we used well validated questionnaires, and while they are not coeliac disease- or 
DH-specific, they are widely used in coeliac disease studies. One limitation in our study is that we 
used volunteers, which might cause selection bias and possibly mislead the life quality being 
superior than it actually is. It must also be conceded that since the availability of gluten-free food is 
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relatively good in Finland and adherence to the GFD is very high, our results may not be directly 
generalizable to different cultures or to countries with poorer dietary adherence.  
5 Conclusions 
 
The aim of this cross-sectional study was to evaluate whether long-term GFD-treated DH 
patients suffer from persistent gastrointestinal symptoms and if they experience a drawdown in 
quality of life. The conclusion was that the gastrointestinal symptoms and the quality of life of long-
term GFD-treated DH patients are comparable to those in the general population. However, women 
with DH suffer from more severe gastrointestinal complaints and inferior vitality compared to DH 
men, which should be recognized during the follow-up.  
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Table 3 Median scores and interquartile ranges for Gastrointestinal Symptoms Rating Scale (GSRS), 
Psychological General Well-Being (PGWB), and Short Form 36 Health Survey (SF-36) questionnaires 
for treated male and female dermatitis herpetiformis (DH) patients. In GSRS higher score indicates 
more symptoms and in PGWB and SF-36 higher score indicates better quality of life. 
 Parameter DH men (n=40) DH women (n=38) P value 
GSRS Total value 1.6 (1.3-2.1) 2.1 (1.5-2.5) 0.006 
 Diarrhoea 1.3 (1.0-1.9) 1.3 (1.0-2.1) 0.328 
 Indigestion 2.0 (1.5-2.8) 2.4 (1.8-3.3) 0.101 
 Constipation 1.3 (1.0-1.7) 1.7 (1.3-2.7) 0.007 
 Pain 1.7 (1.0-2.0) 1.8 (1.3-2.3) 0.077 
 Reflux 1.0 (1.0-2.0) 1.5 (1.0-2.0) 0.199 
PGWB Total score 107 (96-117) 101 (95-109) 0.135 
 Anxiety 24 (21-27) 24 (22-26) 0.717 
 Depression 17 (15-18) 16 (14-18) 0.163 
 Well-being 18 (15-20) 18 (16-19) 0.771 
 Self-control 16 (14-17) 15 (13-17) 0.117 
 General health 13 (12-16) 13 (11-15) 0.160 
 Vitality 19 (17-21) 17 (15-20) 0.052 
SF-36 Physical function 95 (86-100) 93 (75-100) 0.183 
 Role physical 100 (75-100) 100 (73-100) 0.940 
 Role emotional 100 (41.65-100) 100 (33-100) 0.531 
 Vitality 75 (65-85) 70 (49-80) 0.022 
 Mental health 86 (73-91) 80 (68-85) 0.061 
 Social functioning 88 (75-100) 88 (75-100) 0.588 
 Bodily pain 78 (68-90) 78 (54-90) 0.558 
 General health 70 (51-84) 65 (55-80) 0.250 
  
15 
 
15 
 
Figure 1 Short Form 36 Health Survey (SF-36) mean scores and 95% confidence intervals for 
long-term gluten-free diet-treated dermatitis herpetiformis (DH) patients (n=78), Finnish general 
population reference values (n=2060) and treated coeliac disease-controls (n=371). (*Significant 
difference between DH patients and coeliac disease-controls) 
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